BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.